SCHEMBL5844579

SCHEMBL5844579

CCn1c(COc2ccc(CC3SC(=O)NC3=O)cc2)nc2ccccc2c1=O

nearest known ligand 0.80

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
PPARG P37231 10/20 0.80
FFAR1 O14842 11/20 0.70
PPARA Q07869 6/20 0.70
ESRRA P11474 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Balaglitazone SCHEMBL29362039 0.89 PPARG (1.00) PPARGFFAR1PPARAESRRA
Balaglitazone SCHEMBL20125574 0.89 PPARG (1.00) PPARGFFAR1PPARAESRRA
Balaglitazone SCHEMBL20125575 0.89 PPARG (1.00) PPARGFFAR1PPARAESRRA
Balaglitazone SCHEMBL242011 0.89 PPARG (1.00) PPARGFFAR1PPARAESRRA
Balaglitazone SCHEMBL5935616 0.88 PPARG (0.98) PPARGFFAR1PPARAESRRA
Balaglitazone SCHEMBL6359086 0.88 PPARG (0.98) PPARGFFAR1PPARAESRRA
Balaglitazone SCHEMBL5935613 0.88 PPARG (0.98) PPARGFFAR1PPARAESRRA
Balaglitazone SCHEMBL2567779 0.88 PPARG (0.98) PPARGFFAR1PPARAESRRA
Balaglitazone SCHEMBL2567773 0.88 PPARG (0.98) PPARGFFAR1PPARAESRRA
SCHEMBL7836370 0.87 FFAR1 (0.65) PPARGFFAR1PPARAESRRA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7019026-B1 Modulators of Protein Tyrosine Phosphatases (PTPases) NOVO NORDISK A/S (DK) 2006-03-28 US claimed
US-20050032864-A1 Novel heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases DR. REDDY'S LABORATORIES LIMITED 2005-02-10 US claimed
EP-0958296-B1 HETEROCYCLIC COMPOUNDS PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE IN THE TREATMENT OF DIABETES AND RELATED DISEASES REDDYS LAB LTD DR (IN) 2003-07-30 EP claimed
US-6573268-B1 Administering novel azolidinedione derivatives, tautomers, stereoisomers, polymorphs, pharmaceutically acceptable salts and solvates to treat diabetes DR. REDDY'S LABORATORIES LTD. (IN) 2003-06-03 US claimed
US-20020123502-A1 Novel heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases DR. REDDY'S RESEARCH FOUNDATION & REDDY-CHEMINOR, INC. 2002-09-05 US claimed
US-6372750-B2 COMPOUNDS SUCH AS 5-(4-(2-(2,4-DIMETHYL-6-OXO-1,6-DIHYDRO-1-PYRIMIDINYL)ETHOXY)PHENYL METHYL)THIZOLIDINE-2,4-DIONE MADE BY CYCLIZATION, CHEMICAL REDUCTION, HYDROLYSIS, AZOLIDINEDIONE DERIVATIVES DR. REDDY'S RESEARCH FOUNDATION (IN) 2002-04-16 US claimed
US-20010031759-A1 Novel heterocyclic compounds, process for their preparation and pharmaceutical compounds containing them and their use in the treatment of diabetes and related diseases DR. REDDY'S RESEARCH FOUNDATION & REDDY- CHEMINOR, INC. 2001-10-18 US claimed
US-RE39266-E1 Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases DR. REDDY'S LABORATORIES, LIMITED (IN) 2006-09-05 US disclosed
US-20050032864-A1 Novel heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases DR. REDDY'S LABORATORIES LIMITED 2005-02-10 US disclosed
US-6780992-B2 5-(4-(2-(2,4-DIMETHYL-6-OXO-1,6-DIHYDRO-1-PYRIMIDINYL) -ETHOXY)PHENYL METHYL)THIAZOLIDINE-2,4-DIONE FOR EXAMPLE; ALSO OXAZOLIDINE-2,4-DIONE, AND 1,2,4-OXADIAZOLIDINE-3,5-DIONE DERIVATIVES; REDUCING BLOOD GLUCOSE LEVELS DR. REDDY'S LABORATORIES LTD. (IN) 2004-08-24 US disclosed
EP-0958296-B1 HETEROCYCLIC COMPOUNDS PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE IN THE TREATMENT OF DIABETES AND RELATED DISEASES REDDYS LAB LTD DR (IN) 2003-07-30 EP disclosed
US-6573268-B1 Administering novel azolidinedione derivatives, tautomers, stereoisomers, polymorphs, pharmaceutically acceptable salts and solvates to treat diabetes DR. REDDY'S LABORATORIES LTD. (IN) 2003-06-03 US disclosed
US-20020123502-A1 Novel heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases DR. REDDY'S RESEARCH FOUNDATION & REDDY-CHEMINOR, INC. 2002-09-05 US disclosed
US-6372750-B2 COMPOUNDS SUCH AS 5-(4-(2-(2,4-DIMETHYL-6-OXO-1,6-DIHYDRO-1-PYRIMIDINYL)ETHOXY)PHENYL METHYL)THIZOLIDINE-2,4-DIONE MADE BY CYCLIZATION, CHEMICAL REDUCTION, HYDROLYSIS, AZOLIDINEDIONE DERIVATIVES DR. REDDY'S RESEARCH FOUNDATION (IN) 2002-04-16 US disclosed
US-6310069-B1 INTERMEDIATES TO AZOLIDINEDIONE ANTIDIABETIC COMPOUNDS SUCH AS 5-(4-(2-(2,4-DIMETHYL-6-OXO-1,6-DIHYDRO-1-PYRIMIDINYL)ETHOXY)PHENYL METHYL)THIAZOLIDINE-2,4-DIONES DR. REDDY'S RESEARCH FOUNDATION (IN) 2001-10-30 US disclosed
US-20010031759-A1 Novel heterocyclic compounds, process for their preparation and pharmaceutical compounds containing them and their use in the treatment of diabetes and related diseases DR. REDDY'S RESEARCH FOUNDATION & REDDY- CHEMINOR, INC. 2001-10-18 US disclosed
US-6114526-A REACTING AN AMINO DERIVATIVE WITH A HETEROCYCLIC DIONE COMPOUND TO FORM AN ANTIDIABETIC AGENT DR. REDDY'S RESEARCH FOUNDATION (IN) 2000-09-05 US disclosed
US-5985884-A TREATMENT AND/OR PROPHYLAXIS OF DISEASES OR CONDITIONS IN WHICH INSULIN RESISTANCE IS THE UNDERLYING PATHOPHYSIOLOGICAL MECHANISM SUCH AS TYPE II DIABETES, IMPAIRED GLUCOSE TOLERANCE, DYSLIPIDAEMIA, HYPERTENSION, CORONARY HEART DISEASE DR. REDDY'S RESEARCH FOUNDATION (IN) 1999-11-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050032864-A1 Novel heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases IAPP, GPR119, CYP11B2 PPARG 380/4885FFAR1 1350/4885PPARA 664/4885
US-20020123502-A1 Novel heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases IAPP, GPR119, CYP11B1 PPARG 443/4885FFAR1 1148/4885PPARA 769/4885
US-20010031759-A1 Novel heterocyclic compounds, process for their preparation and pharmaceutical compounds containing them and their use in the treatment of diabetes and related diseases IAPP, GPR119, CYP11B1 PPARG 380/4885FFAR1 1277/4885PPARA 651/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.